Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Pasithea Therapeutics Corp. Warrant (KTTAW)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/13/2025: KTTAW (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -95.24% | Avg. Invested days 9 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/13/2025 |
Key Highlights
Company Size ETF | Market Capitalization 0 USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta 0.34 | 52 Weeks Range 0.01 - 0.10 | Updated Date 06/6/2025 |
52 Weeks Range 0.01 - 0.10 | Updated Date 06/6/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) - |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -46.84% | Return on Equity (TTM) -82.81% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value - | Price to Sales(TTM) - |
Enterprise Value - | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding - | Shares Floating 6931236 |
Shares Outstanding - | Shares Floating 6931236 | ||
Percent Insiders - | Percent Institutions - |
Upturn AI SWOT
Pasithea Therapeutics Corp. Warrant
Company Overview
History and Background
Pasithea Therapeutics Corp. is a biotechnology company focused on research and development of novel treatments for neuropsychiatric disorders. Founded in 2019, the company aims to address unmet needs in mental health through innovative therapies.
Core Business Areas
- Drug Development: Focuses on developing pharmaceutical products for neuropsychiatric disorders, including depression and anxiety.
- Clinical Trials: Conducts clinical trials to evaluate the safety and efficacy of its drug candidates.
Leadership and Structure
The leadership team consists of experienced professionals in biotechnology and pharmaceuticals. The organizational structure includes research and development, clinical operations, and business development departments.
Top Products and Market Share
Key Offerings
- PAS-004: A novel compound targeting specific receptors in the brain, aimed at treating neuropsychiatric disorders. Currently in preclinical stages. No market share data available as product is still in development. Competitors include companies developing similar treatments for depression and anxiety.
Market Dynamics
Industry Overview
The neuropsychiatric therapeutics market is experiencing growth due to increasing prevalence of mental health disorders and advancements in neuroscience. The market is competitive, with numerous companies developing novel treatments.
Positioning
Pasithea Therapeutics Corp. is positioned as an innovator in the neuropsychiatric space, focusing on novel treatments. Competitive advantages include a promising drug pipeline and experienced leadership.
Total Addressable Market (TAM)
The global market for neuropsychiatric drugs is estimated at hundreds of billions of dollars. Pasithea aims to capture a portion of this market with its innovative pipeline.
Upturn SWOT Analysis
Strengths
- Novel drug candidates
- Experienced leadership team
- Focus on unmet needs
- Strong intellectual property position
Weaknesses
- Limited financial resources
- Early stage of development
- High regulatory hurdles
- Dependence on successful clinical trials
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion of drug pipeline
- Positive clinical trial results
- Increasing awareness of mental health
Threats
- Failure of clinical trials
- Competition from established pharmaceutical companies
- Regulatory setbacks
- Economic downturn
Competitors and Market Share
Key Competitors
- LLY
- ABBV
- ALKS
- ZTS
Competitive Landscape
Pasithea Therapeutics faces stiff competition from larger, more established pharmaceutical companies. Success depends on clinical trial outcomes and securing partnerships.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is tied to the underlying stock (KTTH).
Future Projections: Future projections are tied to the underlying stock (KTTH) and analyst estimates for Pasithea Therapeutics Corp.
Recent Initiatives: Recent initiatives include advancing drug candidates through preclinical development.
Summary
Pasithea Therapeutics Corp. is a high-risk, high-reward biotechnology company focused on neuropsychiatric disorders. Its success hinges on advancing its drug pipeline through clinical trials and securing partnerships. The company faces significant competition and regulatory hurdles. The warrant (KTTHW) is highly sensitive to the performance of the underlying stock (KTTH).
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings
- Market reports
- Analyst estimates
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. The warrant's value is directly linked to the underlying stock (KTTH) and its associated risks.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Pasithea Therapeutics Corp. Warrant
Exchange NASDAQ | Headquaters Miami Beach, FL, United States | ||
IPO Launch date 2021-09-15 | CEO & Director Dr. Tiago Reis Marques M.D., Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 4 | Website https://www.pasithea.com |
Full time employees 4 | Website https://www.pasithea.com | ||
Pasithea Therapeutics Corp., a clinical-stage biotechnology company, focuses on the discovery, research, and development of treatments for central nervous system (CNS) disorders, RASopathies, and cancers. Its lead product candidate is PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor to treat a range of RASopathies, including neurofibromatosis type 1 (NF1); MAPK pathway-driven tumors, such as BRAFv600 and BRAF fusion tumors; and ETS2 driven diseases, including inflammatory bowel disease (IBD), primary sclerosing cholangitis, and ankylosing spondylitis. The company's lead development candidate is PAS-003, to treat amyotrophic lateral sclerosis. It also intends to develop PAS-001, to treat schizophrenia. Pasithea Therapeutics Corp. was incorporated in 2020 and is headquartered in Miami Beach, Florida.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.